SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 12, 2008--Exelixis, Inc. (Nasdaq:EXEL) announced today that George A. Scangos, PhD, President and Chief Executive Officer of Exelixis, will present at the Lazard Capital Markets 5th Annual Healthcare Conference at 3:10 p.m. EST/12:10 p.m. PST on Tuesday, November 18, 2008. Dr. Scangos will discuss updates to the company's development pipeline and corporate strategy.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.

CONTACT: Exelixis, Inc.
Charles Butler, 650-837-7277 (Investor Contact)
Senior Director
Corporate Communications
& Investor Relations
cbutler@exelixis.com
Soleil Maxwell Harrison, 650-837-7012 (Media Contact)
Senior Manager
Corporate Communications
sharrison@exelixis.com

SOURCE: Exelixis, Inc.